Skip to main content
Erschienen in: Cellular Oncology 2/2020

27.11.2019 | Original paper

BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway

verfasst von: Bo Wang, Chen Cao, Xi Liu, Xin He, Hao Zhuang, Dong Wang, Budong Chen

Erschienen in: Cellular Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

BRCA1-associated protein (BRAP) was first identified by its ability to bind to the nuclear localization signalling motif of BRCA1 and other proteins. Subsequently, human BRAP has been found to exert multiple functions, many of which are related to cancer development. Up till now, however, the role of BRAP in glioma development has remained obscure. Here, we report a role for BRAP in mediating the proliferation and migration of glioma cells both in vitro and in vivo.

Methods

The expression of BRAP in 98 glioma patient samples was determined by immunohistochemistry, after which associations between BRAP expression and patient prognosis were assessed. A short hairpin RNA (shRNA) was used to knock down BRAP and an expression vector was used to exogenously overexpress BRAP in glioma cells. The effects of BRAP expression on tumour cell behaviour in vitro and in an in vivo xenograft mouse model were examined.

Results

We found that in glioma patients BRAP expression was associated with a favourable prognosis. We also found that shRNA-mediated knockdown of BRAP facilitated the proliferation and migration of glioma cells and the self-renewal of glioma stem cells. In parallel, we found that BRAP knockdown increased tumour growth and invasion and decreased survival in an in vivo glioma xenograft mouse model. Mechanistically, we found that BRAP inhibited glioma cell proliferation and migration, as well as glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway.

Conclusions

Together, our findings identify BRAP as a mediator of glioma cell proliferation, migration and glioma stem cell self-renewal.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat K.A. McNeill, Epidemiology of brain tumors. Neurol Clin 34, 981–998 (2016)CrossRef K.A. McNeill, Epidemiology of brain tumors. Neurol Clin 34, 981–998 (2016)CrossRef
2.
Zurück zum Zitat Q.T. Ostrom, H. Gittleman, L. Stetson, S. Virk, J.S. Barnholtz-Sloan, Epidemiology of intracranial Gliomas. Prog Neurol 30, 1–11 (2018) Q.T. Ostrom, H. Gittleman, L. Stetson, S. Virk, J.S. Barnholtz-Sloan, Epidemiology of intracranial Gliomas. Prog Neurol 30, 1–11 (2018)
3.
Zurück zum Zitat R. Stupp, M. Brada, M.J. van den Bent, J.C. Tonn, G. Pentheroudakis, High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3), iii93–ii101 (2014) R. Stupp, M. Brada, M.J. van den Bent, J.C. Tonn, G. Pentheroudakis, High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3), iii93–ii101 (2014)
4.
Zurück zum Zitat D. Matias, J. Balca-Silva, L.G. Dubois, B. Pontes, V.P. Ferrer, L. Rosario, A. do Carmo, J. Echevarria-Lima, A.B. Sarmento-Ribeiro, M.C. Lopes, V. Moura-Neto, Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition. Cell Oncol 40, 247–261 (2017) D. Matias, J. Balca-Silva, L.G. Dubois, B. Pontes, V.P. Ferrer, L. Rosario, A. do Carmo, J. Echevarria-Lima, A.B. Sarmento-Ribeiro, M.C. Lopes, V. Moura-Neto, Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition. Cell Oncol 40, 247–261 (2017)
5.
Zurück zum Zitat J.I. Bastien, K.A. McNeill, H.A. Fine, Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. Cancer 121, 502–516 (2015)CrossRef J.I. Bastien, K.A. McNeill, H.A. Fine, Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. Cancer 121, 502–516 (2015)CrossRef
6.
Zurück zum Zitat S. Li, C.Y. Ku, A.A. Farmer, Y.S. Cong, C.F. Chen, W.H. Lee, Identification of a novel cytoplasmic protein that specifically binds to nuclear localization signal motifs. J Biol Chem 273, 6183–6189 (1998)CrossRef S. Li, C.Y. Ku, A.A. Farmer, Y.S. Cong, C.F. Chen, W.H. Lee, Identification of a novel cytoplasmic protein that specifically binds to nuclear localization signal motifs. J Biol Chem 273, 6183–6189 (1998)CrossRef
7.
Zurück zum Zitat C. Chen, R.E. Lewis, M.A. White, IMP modulates KSR1-dependent multivalent complex formation to specify ERK1/2 pathway activation and response thresholds. J Biol Chem 283, 12789–12796 (2008)CrossRef C. Chen, R.E. Lewis, M.A. White, IMP modulates KSR1-dependent multivalent complex formation to specify ERK1/2 pathway activation and response thresholds. J Biol Chem 283, 12789–12796 (2008)CrossRef
8.
Zurück zum Zitat S.D. Hayes, H. Liu, E. MacDonald, C.M. Sanderson, J.M. Coulson, M.J. Clague, S. Urbe, Direct and indirect control of mitogen-activated protein kinase pathway-associated components, BRAP/IMP E3 ubiquitin ligase and CRAF/RAF1 kinase, by the deubiquitylating enzyme USP15. J Biol Chem 287, 43007–43018 (2012)CrossRef S.D. Hayes, H. Liu, E. MacDonald, C.M. Sanderson, J.M. Coulson, M.J. Clague, S. Urbe, Direct and indirect control of mitogen-activated protein kinase pathway-associated components, BRAP/IMP E3 ubiquitin ligase and CRAF/RAF1 kinase, by the deubiquitylating enzyme USP15. J Biol Chem 287, 43007–43018 (2012)CrossRef
9.
Zurück zum Zitat S.A. Matheny, C. Chen, R.L. Kortum, G.L. Razidlo, R.E. Lewis, M.A. White, Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP. Nature 427, 256–260 (2004)CrossRef S.A. Matheny, C. Chen, R.L. Kortum, G.L. Razidlo, R.E. Lewis, M.A. White, Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP. Nature 427, 256–260 (2004)CrossRef
10.
Zurück zum Zitat S.A. Matheny, M.A. White, Ras-sensitive IMP modulation of the Raf/MEK/ERK cascade through KSR1. Methods Enzymol 407, 237–247 (2006)CrossRef S.A. Matheny, M.A. White, Ras-sensitive IMP modulation of the Raf/MEK/ERK cascade through KSR1. Methods Enzymol 407, 237–247 (2006)CrossRef
11.
Zurück zum Zitat S.A. Matheny, M.A. White, Signaling threshold regulation by the Ras effector IMP. J Biol Chem 284, 11007–11011 (2009)CrossRef S.A. Matheny, M.A. White, Signaling threshold regulation by the Ras effector IMP. J Biol Chem 284, 11007–11011 (2009)CrossRef
12.
Zurück zum Zitat S. Shoji, K. Hanada, N. Ohsawa, M. Shirouzu, Central catalytic domain of BRAP (RNF52) recognizes the types of ubiquitin chains and utilizes oligoubiquitin for ubiquitylation. Biochem J 474, 3207–3226 (2017) S. Shoji, K. Hanada, N. Ohsawa, M. Shirouzu, Central catalytic domain of BRAP (RNF52) recognizes the types of ubiquitin chains and utilizes oligoubiquitin for ubiquitylation. Biochem J 474, 3207–3226 (2017)
13.
Zurück zum Zitat J. Czyzyk, H.C. Chen, K. Bottomly, R.A. Flavell, p21 Ras/impedes mitogenic signal propagation regulates cytokine production and migration in CD4 T cells. J Biol Chem 283, 23004–23015 (2008)CrossRef J. Czyzyk, H.C. Chen, K. Bottomly, R.A. Flavell, p21 Ras/impedes mitogenic signal propagation regulates cytokine production and migration in CD4 T cells. J Biol Chem 283, 23004–23015 (2008)CrossRef
14.
Zurück zum Zitat R.G. Davies, K.M. Wagstaff, E.A. McLaughlin, K.L. Loveland, D.A. Jans, The BRCA1-binding protein BRAP2 can act as a cytoplasmic retention factor for nuclear and nuclear envelope-localizing testicular proteins. Biochim Biophys Acta 1833, 3436–3444 (2013)CrossRef R.G. Davies, K.M. Wagstaff, E.A. McLaughlin, K.L. Loveland, D.A. Jans, The BRCA1-binding protein BRAP2 can act as a cytoplasmic retention factor for nuclear and nuclear envelope-localizing testicular proteins. Biochim Biophys Acta 1833, 3436–3444 (2013)CrossRef
15.
Zurück zum Zitat M. Asada, K. Ohmi, D. Delia, S. Enosawa, S. Suzuki, A. Yuo, H. Suzuki, S. Mizutani, Brap2 functions as a cytoplasmic retention protein for p21 during monocyte differentiation. Mol Cell Biol 24, 8236–8243 (2004)CrossRef M. Asada, K. Ohmi, D. Delia, S. Enosawa, S. Suzuki, A. Yuo, H. Suzuki, S. Mizutani, Brap2 functions as a cytoplasmic retention protein for p21 during monocyte differentiation. Mol Cell Biol 24, 8236–8243 (2004)CrossRef
16.
Zurück zum Zitat A.J. Fulcher, D.M. Roth, S. Fatima, G. Alvisi, D.A. Jans, The BRCA-1 binding protein BRAP2 is a novel, negative regulator of nuclear import of viral proteins, dependent on phosphorylation flanking the nuclear localization signal. FASEB J 24, 1454–1466 (2010) A.J. Fulcher, D.M. Roth, S. Fatima, G. Alvisi, D.A. Jans, The BRCA-1 binding protein BRAP2 is a novel, negative regulator of nuclear import of viral proteins, dependent on phosphorylation flanking the nuclear localization signal. FASEB J 24, 1454–1466 (2010)
17.
Zurück zum Zitat K. Ozaki, H. Sato, K. Inoue, T. Tsunoda, Y. Sakata, H. Mizuno, T.H. Lin, Y. Miyamoto, A. Aoki, Y. Onouchi, S.H. Sheu, S. Ikegawa, K. Odashiro, M. Nobuyoshi, S.H. Juo, M. Hori, Y. Nakamura, T. Tanaka, SNPs in BRAP associated with risk of myocardial infarction in Asian populations. Nat Genet 41, 329–333 (2009)CrossRef K. Ozaki, H. Sato, K. Inoue, T. Tsunoda, Y. Sakata, H. Mizuno, T.H. Lin, Y. Miyamoto, A. Aoki, Y. Onouchi, S.H. Sheu, S. Ikegawa, K. Odashiro, M. Nobuyoshi, S.H. Juo, M. Hori, Y. Nakamura, T. Tanaka, SNPs in BRAP associated with risk of myocardial infarction in Asian populations. Nat Genet 41, 329–333 (2009)CrossRef
18.
Zurück zum Zitat L. Wu, B. Xi, D. Hou, X. Zhao, J. Liu, H. Cheng, Y. Shen, X. Wang, J. Mi, The single nucleotide polymorphisms in BRAP decrease the risk of metabolic syndrome in a Chinese young adult population. Diab Vasc Dis Res 10, 202–207 (2013)CrossRef L. Wu, B. Xi, D. Hou, X. Zhao, J. Liu, H. Cheng, Y. Shen, X. Wang, J. Mi, The single nucleotide polymorphisms in BRAP decrease the risk of metabolic syndrome in a Chinese young adult population. Diab Vasc Dis Res 10, 202–207 (2013)CrossRef
19.
Zurück zum Zitat Y.C. Liao, Y.S. Wang, Y.C. Guo, K. Ozaki, T. Tanaka, H.F. Lin, M.H. Chang, K.C. Chen, M.L. Yu, S.H. Sheu, S.H. Juo, BRAP activates inflammatory cascades and increases the risk for carotid atherosclerosis. Mol Med 17, 1065–1074 (2011)CrossRef Y.C. Liao, Y.S. Wang, Y.C. Guo, K. Ozaki, T. Tanaka, H.F. Lin, M.H. Chang, K.C. Chen, M.L. Yu, S.H. Sheu, S.H. Juo, BRAP activates inflammatory cascades and increases the risk for carotid atherosclerosis. Mol Med 17, 1065–1074 (2011)CrossRef
20.
Zurück zum Zitat F. Zhang, C. Liu, Y. Xu, G. Qi, G. Yuan, Z. Cheng, J. Wang, G. Wang, Z. Wang, W. Zhu, Z. Zhou, X. Zhao, L. Tian, C. Jin, J. Yuan, G. Zhang, Y. Chen, L. Wang, T. Lu, H. Yan, Y. Ruan, W. Yue, D. Zhang, A two-stage association study suggests BRAP as a susceptibility gene for schizophrenia. PLoS One 9, e86037 (2014)CrossRef F. Zhang, C. Liu, Y. Xu, G. Qi, G. Yuan, Z. Cheng, J. Wang, G. Wang, Z. Wang, W. Zhu, Z. Zhou, X. Zhao, L. Tian, C. Jin, J. Yuan, G. Zhang, Y. Chen, L. Wang, T. Lu, H. Yan, Y. Ruan, W. Yue, D. Zhang, A two-stage association study suggests BRAP as a susceptibility gene for schizophrenia. PLoS One 9, e86037 (2014)CrossRef
21.
Zurück zum Zitat J.W. Kim, Y.M. Choe, J.G. Shin, B.L. Park, H.D. Shin, I.G. Choi, B.C. Lee, Associations of BRAP polymorphisms with the risk of alcohol dependence and scores on the alcohol use disorders identification test. Neuropsychiatr Dis Treat 15, 83–94 (2019)CrossRef J.W. Kim, Y.M. Choe, J.G. Shin, B.L. Park, H.D. Shin, I.G. Choi, B.C. Lee, Associations of BRAP polymorphisms with the risk of alcohol dependence and scores on the alcohol use disorders identification test. Neuropsychiatr Dis Treat 15, 83–94 (2019)CrossRef
22.
Zurück zum Zitat Y. Zhao, L. Wei, M. Shao, X. Huang, J. Chang, J. Zheng, J. Chu, Q. Cui, L. Peng, Y. Luo, W. Tan, W. Tan, D. Lin, C. Wu, BRCA1-Associated Protein Increases Invasiveness of Esophageal Squamous Cell Carcinoma. Gastroenterology 153, 1304–1319 e1305 (2017) Y. Zhao, L. Wei, M. Shao, X. Huang, J. Chang, J. Zheng, J. Chu, Q. Cui, L. Peng, Y. Luo, W. Tan, W. Tan, D. Lin, C. Wu, BRCA1-Associated Protein Increases Invasiveness of Esophageal Squamous Cell Carcinoma. Gastroenterology 153, 1304–1319 e1305 (2017)
23.
Zurück zum Zitat J. Tang, S. Xi, G. Wang, B. Wang, S. Yan, Y. Wu, Y. Sang, W. Wu, R. Zhang, T. Kang, Prognostic significance of BRCA1-associated protein 1 in colorectal cancer. Med Oncol 30, 541 (2013)CrossRef J. Tang, S. Xi, G. Wang, B. Wang, S. Yan, Y. Wu, Y. Sang, W. Wu, R. Zhang, T. Kang, Prognostic significance of BRCA1-associated protein 1 in colorectal cancer. Med Oncol 30, 541 (2013)CrossRef
24.
Zurück zum Zitat F.R. Schumacher, S.L. Schmit, S. Jiao, C.K. Edlund, H. Wang, B. Zhang, L. Hsu, S.C. Huang, C.P. Fischer, J.F. Harju, G.E. Idos, F. Lejbkowicz, F.J. Manion, K. McDonnell, C.E. McNeil, M. Melas, H.S. Rennert, W. Shi, D.C. Thomas, D.J. Van Den Berg, C.M. Hutter, A.K. Aragaki, K. Butterbach, B.J. Caan, C.S. Carlson, S.J. Chanock, K.R. Curtis, C.S. Fuchs, M. Gala, E.L. Giovannucc, S.M. Gogarten, R.B. Hayes, B. Henderson, D.J. Hunter, R.D. Jackson, L.N. Kolonel, C. Kooperberg, S. Kury, A. LaCroix, C.C. Laurie, C.A. Laurie, M. Lemire, D. Levine, J. Ma, K.W. Makar, C. Qu, D. Taverna, C.M. Ulrich, K. Wu, S. Kono, D.W. West, S.I. Berndt, S. Bezieau, H. Brenner, P.T. Campbell, A.T. Chan, J. Chang-Claude, G.A. Coetzee, D.V. Conti, D. Duggan, J.C. Figueiredo, B.K. Fortini, S.J. Gallinger, W.J. Gauderman, G. Giles, R. Green, R. Haile, T.A. Harrison, M. Hoffmeister, J.L. Hopper, T.J. Hudson, E. Jacobs, M. Iwasaki, S.H. Jee, M. Jenkins, W.H. Jia, A. Joshi, L. Li, N.M. Lindor, K. Matsuo, V. Moreno, B. Mukherjee, P.A. Newcomb, J.D. Potter, L. Raskin, G. Rennert, S. Rosse, G. Severi, R.E. Schoen, D. Seminara, X.O. Shu, M.L. Slattery, S. Tsugane, E. White, Y.B. Xiang, B.W. Zanke, W. Zheng, L. Le Marchand, G. Casey, S.B. Gruber, U. Peters, Genome-wide association study of colorectal cancer identifies six new susceptibility loci. Nat Commun 6, 7138 (2015)CrossRef F.R. Schumacher, S.L. Schmit, S. Jiao, C.K. Edlund, H. Wang, B. Zhang, L. Hsu, S.C. Huang, C.P. Fischer, J.F. Harju, G.E. Idos, F. Lejbkowicz, F.J. Manion, K. McDonnell, C.E. McNeil, M. Melas, H.S. Rennert, W. Shi, D.C. Thomas, D.J. Van Den Berg, C.M. Hutter, A.K. Aragaki, K. Butterbach, B.J. Caan, C.S. Carlson, S.J. Chanock, K.R. Curtis, C.S. Fuchs, M. Gala, E.L. Giovannucc, S.M. Gogarten, R.B. Hayes, B. Henderson, D.J. Hunter, R.D. Jackson, L.N. Kolonel, C. Kooperberg, S. Kury, A. LaCroix, C.C. Laurie, C.A. Laurie, M. Lemire, D. Levine, J. Ma, K.W. Makar, C. Qu, D. Taverna, C.M. Ulrich, K. Wu, S. Kono, D.W. West, S.I. Berndt, S. Bezieau, H. Brenner, P.T. Campbell, A.T. Chan, J. Chang-Claude, G.A. Coetzee, D.V. Conti, D. Duggan, J.C. Figueiredo, B.K. Fortini, S.J. Gallinger, W.J. Gauderman, G. Giles, R. Green, R. Haile, T.A. Harrison, M. Hoffmeister, J.L. Hopper, T.J. Hudson, E. Jacobs, M. Iwasaki, S.H. Jee, M. Jenkins, W.H. Jia, A. Joshi, L. Li, N.M. Lindor, K. Matsuo, V. Moreno, B. Mukherjee, P.A. Newcomb, J.D. Potter, L. Raskin, G. Rennert, S. Rosse, G. Severi, R.E. Schoen, D. Seminara, X.O. Shu, M.L. Slattery, S. Tsugane, E. White, Y.B. Xiang, B.W. Zanke, W. Zheng, L. Le Marchand, G. Casey, S.B. Gruber, U. Peters, Genome-wide association study of colorectal cancer identifies six new susceptibility loci. Nat Commun 6, 7138 (2015)CrossRef
25.
Zurück zum Zitat R.J. Gilbertson, J.N. Rich, Making a tumour's bed: Glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7, 733–736 (2007)CrossRef R.J. Gilbertson, J.N. Rich, Making a tumour's bed: Glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7, 733–736 (2007)CrossRef
26.
Zurück zum Zitat J. Marjanovic Vicentic, D. Drakulic, I. Garcia, V. Vukovic, P. Aldaz, N. Puskas, I. Nikolic, G. Tasic, S. Raicevic, L. Garros-Regulez, N. Sampron, M.J. Atkinson, N. Anastasov, A. Matheu, M. Stevanovic, SOX3 can promote the malignant behavior of glioblastoma cells. Cell Oncol 42, 41–54 (2019)CrossRef J. Marjanovic Vicentic, D. Drakulic, I. Garcia, V. Vukovic, P. Aldaz, N. Puskas, I. Nikolic, G. Tasic, S. Raicevic, L. Garros-Regulez, N. Sampron, M.J. Atkinson, N. Anastasov, A. Matheu, M. Stevanovic, SOX3 can promote the malignant behavior of glioblastoma cells. Cell Oncol 42, 41–54 (2019)CrossRef
27.
Zurück zum Zitat L.M. Nusblat, M.J. Carroll, C.M. Roth, Crosstalk between M2 macrophages and glioma stem cells. Cell Oncol 40, 471–482 (2017)CrossRef L.M. Nusblat, M.J. Carroll, C.M. Roth, Crosstalk between M2 macrophages and glioma stem cells. Cell Oncol 40, 471–482 (2017)CrossRef
28.
Zurück zum Zitat C.D. Stiles, D.H. Rowitch, Glioma stem cells: a midterm exam. Neuron 58, 832–846 (2008)CrossRef C.D. Stiles, D.H. Rowitch, Glioma stem cells: a midterm exam. Neuron 58, 832–846 (2008)CrossRef
29.
Zurück zum Zitat I. Pastushenko, C. Blanpain, EMT transition states during tumor progression and metastasis. Trends Cell Biol 29, 212–226 (2019)CrossRef I. Pastushenko, C. Blanpain, EMT transition states during tumor progression and metastasis. Trends Cell Biol 29, 212–226 (2019)CrossRef
30.
Zurück zum Zitat T. Brabletz, R. Kalluri, M.A. Nieto, R.A. Weinberg, EMT in cancer. Nat Rev Cancer 18, 128–134 (2018)CrossRef T. Brabletz, R. Kalluri, M.A. Nieto, R.A. Weinberg, EMT in cancer. Nat Rev Cancer 18, 128–134 (2018)CrossRef
31.
Zurück zum Zitat L. Zhang, F. Zhou, P. ten Dijke, Signaling interplay between transforming growth factor-beta receptor and PI3K/AKT pathways in cancer. Trends Biochem Sci 38, 612–620 (2013)CrossRef L. Zhang, F. Zhou, P. ten Dijke, Signaling interplay between transforming growth factor-beta receptor and PI3K/AKT pathways in cancer. Trends Biochem Sci 38, 612–620 (2013)CrossRef
32.
Zurück zum Zitat D.A. Fruman, C. Rommel, PI3K and cancer: Lessons, challenges and opportunities. Nat Rev Drug Discov 13, 140–156 (2014)CrossRef D.A. Fruman, C. Rommel, PI3K and cancer: Lessons, challenges and opportunities. Nat Rev Drug Discov 13, 140–156 (2014)CrossRef
33.
Zurück zum Zitat R. Grant, L. Kolb, J. Moliterno, Molecular and genetic pathways in gliomas: The future of personalized therapeutics. CNS Oncology 3, 123–136 (2014)CrossRef R. Grant, L. Kolb, J. Moliterno, Molecular and genetic pathways in gliomas: The future of personalized therapeutics. CNS Oncology 3, 123–136 (2014)CrossRef
34.
Zurück zum Zitat B. Markman, F. Atzori, J. Perez-Garcia, J. Tabernero, J. Baselga, Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 21, 683–691 (2010) B. Markman, F. Atzori, J. Perez-Garcia, J. Tabernero, J. Baselga, Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 21, 683–691 (2010)
35.
Zurück zum Zitat J. Polivka Jr., F. Janku, Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 142, 164–175 (2014)CrossRef J. Polivka Jr., F. Janku, Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 142, 164–175 (2014)CrossRef
36.
Zurück zum Zitat L.M. Thorpe, H. Yuzugullu, J.J. Zhao, PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15, 7–24 (2015)CrossRef L.M. Thorpe, H. Yuzugullu, J.J. Zhao, PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15, 7–24 (2015)CrossRef
Metadaten
Titel
BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway
verfasst von
Bo Wang
Chen Cao
Xi Liu
Xin He
Hao Zhuang
Dong Wang
Budong Chen
Publikationsdatum
27.11.2019
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 2/2020
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-019-00482-8

Weitere Artikel der Ausgabe 2/2020

Cellular Oncology 2/2020 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …